CN111450172A - 一种抑制人结直肠癌细胞sw480增殖的红茶提取物及其应用 - Google Patents
一种抑制人结直肠癌细胞sw480增殖的红茶提取物及其应用 Download PDFInfo
- Publication number
- CN111450172A CN111450172A CN202010017308.2A CN202010017308A CN111450172A CN 111450172 A CN111450172 A CN 111450172A CN 202010017308 A CN202010017308 A CN 202010017308A CN 111450172 A CN111450172 A CN 111450172A
- Authority
- CN
- China
- Prior art keywords
- black tea
- tea extract
- colorectal cancer
- proliferation
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000269722 Thea sinensis Species 0.000 title claims abstract description 59
- 235000006468 Thea sinensis Nutrition 0.000 title claims abstract description 50
- 235000020279 black tea Nutrition 0.000 title claims abstract description 49
- 239000000284 extract Substances 0.000 title claims abstract description 42
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 24
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims abstract description 22
- 230000035755 proliferation Effects 0.000 title claims abstract description 15
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 12
- 235000013616 tea Nutrition 0.000 claims abstract description 8
- 239000000706 filtrate Substances 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 235000013305 food Nutrition 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000012545 processing Methods 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 5
- 238000003809 water extraction Methods 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000009702 cancer cell proliferation Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000000643 oven drying Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/22—Drying or concentrating tea extract
- A23F3/26—Drying or concentrating tea extract by lyophilisation
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/30—Further treatment of dried tea extract; Preparations produced thereby, e.g. instant tea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及一种抑制人结直肠癌细胞SW480增殖的红茶提取物及其应用，属于茶加工技术领域。该红茶提取物经如下步骤得到：红茶超微粉碎，用粉碎后的茶叶:沸水=1g：1‑200mL的比例浸提40分钟，过滤得到滤液，重复上述浸提步骤2次，合并滤液，滤液经传统的浓缩、干燥后即得。细胞试验表明，此红茶提取物能显著抑制人结直肠癌细胞SW480的增殖，能作为爱吃红肉人士的健康伴侣，应用于食品和保健品中。
Description
技术领域
本发明属于茶加工技术领域，具体的说，涉及一种抑制人结直肠癌细胞SW480增殖的红茶提取物及其应用。
背景技术
结直肠癌是世界常见的恶性肿瘤之一。30年来，我国结直肠癌发病率年均上升3％～4％。我国结直肠癌发病率和死亡例数分别占全世界发病和死亡总例数的18.6％和20.1％，均居第1位。根据国家癌症中心全国肿瘤登记数据报告，我国城市和农村地区结直肠癌发病率分别列所有恶性肿瘤的第3位及第5位，病死率分别居第4位和第5位。尽管当前结肠癌治疗方面涌出一些新的方法，如西妥昔单抗、贝伐单抗等分子靶向药物，但总体上来看结肠癌治疗效果仍然较差，尚无满意的非侵入性治疗方案。
红茶是世界生产和消费的主要茶类，其消费量高于绿茶和乌龙茶。研究表明红茶具有多种生物活性，如抗氧化、防止动脉粥样硬化、减肥、抗炎症、抗肿瘤及调节代谢综合征等。本发明以红茶为原料，制备一种具有抑制人结直肠癌细胞SW480增殖的红茶提取物。经文献检索，未见与本发明相同的公开报道。
发明内容
本发明是目的在于提供一种能抑制人结直肠癌细胞SW480增殖的红茶提取物及其应用，
为实现上述目的，本发明是通过以下技术方案实现的：
所述的红茶提取物，采用水浸提法制备而得，具体包括以下步骤：红茶超微粉碎，用粉碎后的茶叶:沸水＝1g：1-200mL的比例浸提1-60分钟，过滤得到滤液，重复上述浸提步骤2次，合并滤液，滤液经浓缩、干燥后即得红茶提取物。
进一步优选，所述干燥采用真空冷冻干燥。
进一步优选，所述干燥采用40-80℃条件下烘干处理。
红茶提取物在抑制人结直肠癌细胞SW480增殖产品中的应用，所述红茶提取物为冻干粉或烘干粉。
红茶提取物在抑制人结直肠癌细胞SW480增殖产品中的应用，所述红茶提取物是利用上述制备方法获得。
红茶提取物在食品和保健品中的应用，所述红茶提取物为冻干粉或烘干粉。
红茶提取物在食品和保健品中的应用，所述红茶提取物是利用上述制备方法获得。
本发明的有益效果：该红茶提取物富含茶多酚、茶色素、蛋白质及多糖，能抑制人结直肠癌细胞SW480的增殖，可应用于食品和保健品中。
具体实施方式
为了使本发明的目的、技术方案和有益效果更加清楚，下面将对本发明的优选实施例进行详细的说明，以方便技术人员理解。
【实施例1】
红茶提取物，采用水浸提法制备而得，具体步骤如下：红茶超微粉碎，用粉碎后的茶叶:沸水＝1g：10mL的比例浸提40分钟，过滤得到滤液，重复上述浸提步骤2次，合并滤液，滤液减压浓缩后，经真空冷冻干燥，得到红茶提取物(冻干)。
【实施例2】
红茶提取物，采用水浸提法制备而得，具体步骤如下：红茶超微粉碎，用粉碎后的茶叶:沸水＝1g：10mL的比例浸提40分钟，过滤得到滤液，重复上述浸提步骤2次，合并滤液，滤液减压浓缩后，浓缩液在65℃下烘干，得到红茶提取物(烘干)。
实施分析
将实施例1、2得到的红茶提取物进行细胞试验用MTT法检测红茶提取物对人结直肠癌细胞SW480增殖的影响，其结果如下：从表1可看出，随着培养时间的延长，用不同浓度的红茶提取物(冻干或烘干)培养的人结直肠癌细胞SW480相对存活率均降低，表明红茶提取物能抑制人结直肠癌细胞SW480增殖。采用不同浓度的红茶提取物(冻干)培养SW480细胞，培养时间大于24h后才显示抑制癌细胞增殖的作用；而采用不同浓度的红茶提取物(烘干)培养SW480细胞，培养时间为24h时即显示抑制癌细胞增殖的作用。不同浓度的红茶提取物(冻干或烘干)对人结直肠癌细胞SW480增殖的抑制作用剂量效应关系不明显。
表1红茶提取物对人结直肠癌细胞SW480相对存活率的影响
注：同列间大写字母肩标相同者，差异不显著(P>0.05)，同列间大写字母肩标不同者，差异显著(P<0.05)；同行间小写字母肩标相同者，差异不显著(P>0.05)，同行间小写字母肩标不同者，差异显著(P<0.05)。
研究结果表明：该红茶提取物能抑制人结直肠癌细胞SW480的增殖，能直接加工成粉剂、胶囊、含片及饮料等，使用方便，便于携带；也能够作为添加剂用于食品中。
最后说明的是，以上优选实施例仅用于说明本发明的技术方案而非限制，尽管通过上述优选实施例已经对本发明进行了详细的描述，但本领域技术人员应当理解，可以在形式上和细节上对其作出各种各样的改变，而不偏离本发明权利要求书所限定的范围。
Claims (7)
1.一种红茶提取物，其特征在于：其制备方法包括以下步骤：红茶超微粉碎，用粉碎后的茶叶:沸水=1g：1-200mL的比例浸提1-60分钟，过滤得到滤液，重复上述浸提步骤2次，合并滤液，滤液经浓缩、干燥后，即得红茶提取物。
2.根据权利要求1所述的一种红茶提取物，其特征在于：所述干燥采用真空冷冻干燥。
3.根据权利要求1所述的一种红茶提取物，其特征在于：所述干燥采用40-80℃条件下烘干处理。
4.红茶提取物在抑制人结直肠癌细胞SW480增殖产品中的应用，其特征在于：所述红茶提取物为冻干粉或烘干粉。
5.红茶提取物在抑制人结直肠癌细胞SW480增殖产品中的应用，其特征在于：所述红茶提取物是利用权利要求1-3任一项所述的制备方法获得。
6.红茶提取物在食品和保健品中的应用，其特征在于：所述红茶提取物为冻干粉或烘干粉。
7.红茶提取物在食品和保健品中的应用，其特征在于：所述红茶提取物是利用权利要求1-3任一项所述的制备方法获得。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010017308.2A CN111450172A (zh) | 2020-01-08 | 2020-01-08 | 一种抑制人结直肠癌细胞sw480增殖的红茶提取物及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010017308.2A CN111450172A (zh) | 2020-01-08 | 2020-01-08 | 一种抑制人结直肠癌细胞sw480增殖的红茶提取物及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111450172A true CN111450172A (zh) | 2020-07-28 |
Family
ID=71671777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010017308.2A Pending CN111450172A (zh) | 2020-01-08 | 2020-01-08 | 一种抑制人结直肠癌细胞sw480增殖的红茶提取物及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111450172A (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106256357A (zh) * | 2016-08-10 | 2016-12-28 | 广东省农业科学院茶叶研究所 | 一种具有抗氧化和辅助降血脂功效的红茶复合物 |
-
2020
- 2020-01-08 CN CN202010017308.2A patent/CN111450172A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106256357A (zh) * | 2016-08-10 | 2016-12-28 | 广东省农业科学院茶叶研究所 | 一种具有抗氧化和辅助降血脂功效的红茶复合物 |
Non-Patent Citations (3)
| Title |
|---|
| 上海信裕生物科技有限公司: "LoVo细胞说明书", 《HTTP://WWW.BIOON.COM.CN/DOC/SHOWARTICLE.ASP?NEWSID=67346》 * |
| 生物谷: "SW480细胞说明书", 《HTTP://WWW.BIOON.COM.CN/SUB/SHOWARTICLE.ASP?NEWSID=68955》 * |
| 谭晓华等: "茶叶水提取物诱导LoVo细胞凋亡的差异", 《世界华人消化杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8183031B2 (en) | Composition containing β-glucan, method of producing the same and foods, drinks or skin moisturizers containing the composition | |
| CN103315362B (zh) | 一种茯苓固态发酵功能饮品及制备方法 | |
| CN103142661B (zh) | 一种桦褐孔菌水提精粉的制备方法 | |
| KR20080113175A (ko) | 상황버섯을 이용한 기능성 음료의 제조방법 및 이에 따른 생산품 | |
| CN109276576A (zh) | 白肉灵芝多糖在制备抗肿瘤药物中的用途 | |
| KR101377586B1 (ko) | 고상 발효에 의한 항산화 활성 및 총 페놀 화합물 함량이 증진된 차가버섯 발효물의 제조방법 | |
| CN110946196A (zh) | 木姜叶柯冲剂及制备方法 | |
| CN105754809B (zh) | 一种工业化生产有机富硒藏虫草原浆酒的方法及所得产物 | |
| Wen et al. | Immunoregenerative effects of the bionically cultured Sanghuang mushrooms (Inonotus sanghuagn) on the immunodeficient mice | |
| CN114874344A (zh) | 青稞嫩叶碱提多糖的制备方法及其应用 | |
| CN108158884A (zh) | 具有抑制过敏、延缓衰老功效的化妆品原料组合物及其在化妆品中的应用 | |
| JP4022747B2 (ja) | アガリクス茸エキスの製造方法 | |
| CN111450172A (zh) | 一种抑制人结直肠癌细胞sw480增殖的红茶提取物及其应用 | |
| CN107173805B (zh) | 一种具有防治肺癌功能的保健食品 | |
| KR101216113B1 (ko) | 항여드름 효능 및 주름개선 효능을 가지며 향취가 개선된 프로폴리스 가용 분획물 및 그 제조방법 | |
| KR20160124438A (ko) | 다시마, 오크라 및 참마 혼합 추출물을 포함하는 화장품 조성물 및 그 제조 방법 | |
| CN108938677A (zh) | 一种具有治疗乳腺癌作用的匍枝马尾藻提取物及其制备方法与应用 | |
| CN101810651A (zh) | 具有抑制肿瘤作用的猕猴桃冷冻干燥果素制品的制备方法 | |
| CN105456308B (zh) | 一种治疗肺鳞癌的马尾松树皮提取物及其制备方法与其组合物 | |
| CN109160947B (zh) | 一种螺旋藻藻蓝蛋白的制备方法及其应用 | |
| KR101968891B1 (ko) | 멀꿀 열매 추출물을 유효성분으로 포함하는 혈중알콜농도 저감 촉진용 조성물 | |
| KR102218224B1 (ko) | 곤달비잎의 발효물을 유효성분으로 함유하는 피부염증 또는 피부노화의 예방 또는 개선용 화장료 조성물 | |
| CN111436607A (zh) | 一种抑制人结直肠癌细胞sw480增殖的玫瑰花提取物及其应用 | |
| CN110754553A (zh) | 预防癌症的益生菌发酵药食同源中药茶饮料及制备方法 | |
| CN102851345B (zh) | 小球藻抗肿瘤多肽的制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200728 |
|
| RJ01 | Rejection of invention patent application after publication |